{
    "nctId": "NCT00236899",
    "briefTitle": "Phase III Study of Two Different Schedules (Weekly and Tri-weekly) of Combination of Gemcitabine and Two Taxanes in MBC",
    "officialTitle": "A Randomized Phase III Trial of Gemcitabine and Docetaxel Versus Gemcitabine and Paclitaxel in Patients With Metastatic Breast Cancer: A Comparison of Different Schedules",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer (MBC)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 241,
    "primaryOutcomeMeasure": "Time to Progressive Disease (TTPD) by Treatment Schedule",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologic diagnosis of metastatic breast cancer (MBC).\n* Prior neoadjuvant or adjuvant taxanes regimen is allowed if \u226512 months since completion of the regimen.\n* Relapsing after receiving one adjuvant/neoadjuvant chemotherapy containing an anthracycline if not clinically contraindicated.\n* Patients with measurable disease.\n* Previous hormonal therapy for adjuvant setting or metastatic disease.\n\nExclusion Criteria:\n\n* Previous chemotherapy for MBC\n* Previous chemotherapy with gemcitabine in any setting of disease\n* Patient candidable to treatment with trastuzumab.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}